Table 1 Relationship between STMN1 expression and clinicopathological parameters
From: Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer
Characteristics | No. of patients | Low expression | High expression | P-value |
|---|---|---|---|---|
Gender | ||||
Male | 72 (63.7%) | 37 (51.4%) | 35 (48.6%) | 0.557 |
Female | 41 (36.3%) | 24(58.5%) | 17 (41.5%) | |
Age (years) | ||||
≤65 | 64 (56.6%) | 32 (50.0%) | 32 (50.0%) | 0.348 |
>65 | 49 (43.4%) | 29 (49.2%) | 20 (40.8%) | |
Smoking status | ||||
No | 60 (53.1%) | 30 (50.0%) | 30 (50.0%) | 0.450 |
Yes | 53 (46.9%) | 31 (58.8%) | 22 (41.5%) | |
p53 expression | ||||
Negative | 51 (45.1%) | 23 (45.1%) | 28 (54.9%) | 0.531 |
Positive | 62 (54.9%) | 33 (53.2%) | 29 (46.8%) | |
Histology | ||||
Squamous cell carcinoma | 45 (39.8%) | 22 (48.9%) | 23 (51.5%) | 0.442 |
Adenocarcinoma | 68 (60.2%) | 39 (57.4%) | 29 (42.6%) | |
Differentiation | ||||
Moderate–well | 65 (57.5%) | 46 (70.8%) | 19 (29.2%) | 0.000* |
Poor | 48 (42.5%) | 15 (31.3%) | 33 (68.8%) | |
Tumor size (cm) | ||||
≤3 | 64 (56.6%) | 41 (64.1%) | 23 (35.9%) | 0.022* |
>3 | 49 (43.4%) | 20 (40.8%) | 29 (59.2%) | |
N stage | ||||
N0 | 42 (37.2%) | 28 (66.7%) | 14 (33.3%) | 0.033* |
N1+N2 | 71 (62.8%) | 33 (46.5%) | 38 (53.5%) | |
TNM stage | ||||
I+II | 74 (65.5%) | 53 (71.6%) | 21 (28.4%) | 0.000* |
III | 39 (34.5%) | 15 (38.5%) | 24 (61.5%) | |
